In 2014, the American Food and Drug Administration and the European Medicines Agency approved the use of TIMP2*IGFBP7, urinary markers of cell cycle arrest reflecting cellular stress preceding tissue damage, to aid in the early prediction of AKI, with advantages in terms of diagnostic precocity and prognosis when compared to creatinine rise or urinary output reduction [6]. The gene discussed is TIMP2; the disease is acute kidney injury.